Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci. 2007;28:334–41.

CAS  PubMed  Article  Google Scholar 

Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem. 1999;274:21873–7.

CAS  PubMed  Article  Google Scholar 

Veit G, Avramescu RG, Chiang AN, Houck SA, Cai Z, Peters KW, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016;27:424–33.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–72.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Singh AK, Fan Y, Balut C, Alani S, Manelli AM, Swensen AM, et al. Biological characterization of F508delCFTR protein processing by the CFTR Corrector ABBV-2222/GLPG2222. J Pharmacol Exp Ther. 2020;372:107–18.

CAS  PubMed  Article  Google Scholar 

Crawford DK, Mullenders J, Pott J, Boj SF, Landskroner-Eiger S, Goddeeris MM. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids. J Cyst Fibros. 2021;20:436–42.

CAS  PubMed  Article  Google Scholar 

Leubitz A, Frydman-Marom A, Sharpe N, van Duzer J, Campbell KCM, Vanhoutte F. Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:984–94.

CAS  PubMed  Article  Google Scholar 

Carotti M, Scano M, Fancello I, Richard I, Risato G, Bensalah M, et al. Combined use of CFTR correctors in LGMD2D myotubes improves sarcoglycan complex recovery. Int J Mol Sci. 2020;21:1813.

CAS  PubMed Central  Article  Google Scholar 

Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009;461:272–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Trujillano D, Ramos MD, González J, Tornador C, Sotillo F, Escaramis G, et al. Next generation diagnostics of cystic fibrosis and CFTR-related disorders by targeted multiplex high-coverage resequencing of CFTR. J Med Genet. 2013;50:455–62.

CAS  PubMed  Article  Google Scholar 

Abou Tayoun AN, Tunkey CD, Pugh TJ, Ross T, Shah M, Lee CC, et al. A comprehensive assay for CFTR mutational analysis using next-generation sequencing. Clin Chem. 2013;59:1481–8.

CAS  PubMed  Article  Google Scholar 

Bonini J, Varilh J, Raynal C, Thèze C, Beyne E, Audrezet M-P, et al. Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis. Genet Med Off J Am Coll Med Genet. 2015;17:796–806.

CAS  Google Scholar 

Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.

CAS  PubMed  Article  Google Scholar 

Zavolan M, Kondo S, Schonbach C, Adachi J, Hume DA, Hayashizaki Y, et al. Impact of alternative initiation, splicing, and termination on the diversity of the mRNA transcripts encoded by the mouse transcriptome. Genome Res. 2003;13:1290–1300.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018;59:253–68.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Maquat LE. When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. RNA N Y N. 1995;1:453–65.

CAS  Google Scholar 

Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Krawczak M, Thomas NST, Hundrieser B, Mort M, Wittig M, Hampe J, et al. Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat. 2007;28:150–8.

CAS  PubMed  Article  Google Scholar 

Amaral MD. Processing of CFTR: traversing the cellular maze-How much CFTR needs to go through to avoid cystic fibrosis? CFTR processing and traffic. Pediatr Pulmonol. 2005;39:479–91.

PubMed  Article  Google Scholar 

Ramalho AS, Beck S, Penque D, Gonska T, Seydewitz HH, Mall M, et al. Transcript analysis of the cystic fibrosis splicing mutation 1525-1G>A shows use of multiple alternative splicing sites and suggests a putative role of exonic splicing enhancers. J Med Genet. 2003;40:e88.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Claustres M, Guittard C, Bozon D, Chevalier F, Verlingue C, Ferec C, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat. 2000;16:143–56.

CAS  PubMed  Article  Google Scholar 

Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med. 1997;155:1914–20.

CAS  PubMed  Article  Google Scholar 

Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest. 1998;101:487–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Claustres M, Thèze C, des Georges M, Baux D, Girodon E, Bienvenu T, et al. CFTR -France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants. Hum Mutat. 2017;38:1297–315.

CAS  PubMed  Article  Google Scholar 

Will K, Dörk T, Stuhrmann M, Hardt HVD, Ellemunter H, Tümmler B, et al. Transcript analysis of CFTR nonsense mutations in lymphocytes and nasal epithelial cells from cystic fibrosis patients. Hum Mutat. 1995;5:210–20.

CAS  PubMed  Article  Google Scholar 

Aznarez I, Zielenski J, Rommens JM, Blencowe BJ, Tsui L-C. Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X. J Med Genet. 2007;44:341–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Aissat A, de Becdelièvre A, Golmard L, Vasseur C, Costa C, Chaoui A, et al. Combined computational-experimental analyses of CFTR exon strength uncover predictability of exon-skipping level. Hum Mutat. 2013;34:873–81.

CAS  PubMed  Article  Google Scholar 

Raynal C, Baux D, Theze C, Bareil C, Taulan M, Roux A-F, et al. A classification model relative to splicing for variants of unknown clinical significance: application to the CFTR gene. Hum Mutat. 2013;34:774–84.

CAS  PubMed  Article  Google Scholar 

Soukarieh O, Gaildrat P, Hamieh M, Drouet A, Baert-Desurmont S, Frébourg T, et al. Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools. PLoS Genet. 2016;12:e1005756.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Martin N, Bergougnoux A, Baatallah N, Chevalier B, Varilh J, Baux D, et al. Exon identity influences splicing induced by exonic variants and in silico prediction efficacy. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2021;20:464–72.

CAS  Article  Google Scholar 

Hinzpeter A, Aissat A, Sondo E, Costa C, Arous N, Gameiro C, et al. Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier. PLoS Genet. 2010;6:e1001153.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Hiller M, Huse K, Szafranski K, Jahn N, Hampe J, Schreiber S, et al. Widespread occurrence of alternative splicing at NAGNAG acceptors contributes to proteome plasticity. Nat Genet. 2004;36:1255–7.

CAS  PubMed  Article  Google Scholar 

Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285–98.

CAS  PubMed  Article  Google Scholar 

Sharma N, Evans TA, Pellicore MJ, Davis E, Aksit MA, McCague AF, et al. Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis. PLoS Genet. 2018;14:e1007723.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Morris-Rosendahl DJ, Edwards M, McDonnell MJ, John S, Alton EWFW, Davies JC. et al. Whole-gene sequencing of CFTR reveals a high prevalence of the intronic variant c.3874-4522A>G in cystic fibrosis. Am J Respir Crit Care Med. 2020;201:1438–41.

PubMed  Article  Google Scholar 

Woolfe A, Mullikin JC, Elnitski L. Genomic features defining exonic variants that modulate splicing. Genome Biol. 2010;11:R20.

PubMed  PubMed Central  Article  CAS